长春安沃高新生物制药有限公司成立于2019年3月,注册资本为2亿美元，坐落在长春市高新北区北湖开发区，是由长春高新技术产业（集团）股份有限公司与冰岛Alvotech.Hf（安沃泰克）合资建立的集靶向抗体药物研发、生产、销售于一体的高新技术企业,公司引进的6个品种均属于“重磅***”级别，2018年的销售额均超过20亿美元，其中阿达木单抗连续6年蝉联全球药王之位，2018年的销售额近200亿美元。公司2019年开始施工建设，建设周期2-3年，预计2022年***款产品上市，五年内实现两个产品上市，4个产品进入临床，同时适时启动公司的IPO。到2030年，估计营业收入可达60亿元、净利润15亿元、税金5亿元。 Changchun Alvotech &CCHN Bio-Pharmaceutical Co,Ltd.was founded in March 2019 by Alvotech Hf and Changchun High-tech Industry (Group) Co,Ltd, which had a registered capital of US $200 million. The company is located in Changchun Beihu Science and Technology Development Zone, China. Changchun Alvotech &CCHN Bio-Pharmaceutical Co,Ltd.is engaged in the research and development, production, sales in one of the high-tech JV.The six varieties introduced by Alvotech & CCHN all belong to the “ heavy bomb” class, with sales of more than $2 billion in 2018, of which adalimumab has been the world drug king for 6 consecutive years, with the sales of nearly $20 billion in 2018.Construction began in 2019, with a construction period of 2-3 years. Alvotech & CCHN's first product will be on the market in 2022, two products will be launched in the next five year, and the remaining four products will be in the clinical research stage. At the same time, company's IPO will be launched. By the 2030, it is conservatively estimated that revenue will reach to 6 billion RMB, net profit will be 1.5 billion RMB, and tax will be 500 million RMB.